Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Advertisement
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

RWD Key To Scottish Orkambi Deal

Vertex has managed to secure a deal to provide Scottish cystic fibrosis patients with access to Orkambi and Symkevi. The promise of real world data and a price discount has convinced the Scottish government to say yes to the treatments, which had earlier been rejected by the Scottish Medicines Consortium.

Europe United Kingdom

How To Pay For The New Wave Of Gene Therapies

New models of paying for gene therapies will emerge as more of these innovative treatments, particularly outside the rare disease and oncology spaces, hit the market.

Health Technology Assessment Government Payers

How To Pay For The New Wave Of Gene Therapies

New models of paying for gene therapies will emerge as more of these innovative treatments, particularly outside the rare disease and oncology spaces, hit the market.

Health Technology Assessment Government Payers

Industry Guidance Highlights 'Triple Wins' From Joint Work With UK NHS

The UK drug industry association, the ABPI, has unveiled new guidance for joint working projects between industry and the National Health Service.

Dutch Heath Minister Accused Of Polarizing Medicine Price Debate

Dutch Health Minister Bruno Bruins has attacked pharmaceutical companies over their drug pricing practices, and has threatened to name and shame one particular firm.

Europe Netherlands

Brazil ‘Internationalizes’ GMP Regulatory Framework

Brazilian medicines regulator Anvisa has approved a new regulatory framework for good manufacturing practices, bringing it into line with PIC/S standards.

South America Brazil
See All
Advertisement
UsernamePublicRestriction

Register